Pseudobulbar affect: The spectrum of clinical presentations, etiologies and treatments

Expert Review of Neurotherapeutics

Volumn 11, Issue 7, 2011, Pages 1077-1088

  Miller, Ariel ^a   Pratt, Hillel ^a   Schiffer, Randolph B ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Evoked Potentials Laboratory ^*  (United States)

Author keywords

cerebellum; corticopontinecerebellar circuit; dextromethorphan quinidine; event related potentials; involuntary emotional expression disorder; pseudobulbar affect; selective serotonin reuptake Inhibitors; tricyclic antidepressants

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DEXTROMETHORPHAN; FLUOXETINE; NEUROTRANSMITTER; NORTRIPTYLINE; PLACEBO; QUINIDINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AMYOTROPHIC LATERAL SCLEROSIS; CELL TYPE; CEREBELLUM; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; EMOTION; EVENT RELATED POTENTIAL; GLUTAMATERGIC TRANSMISSION; HIP FRACTURE; HUMAN; INSOMNIA; LIFE EXPECTANCY; MOOD DISORDER; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NAUSEA; NEUROANATOMY; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTRANSMISSION; NONVERBAL COMMUNICATION; PATHOLOGICAL CRYING; PATHOLOGICAL LAUGHTER; PATHOPHYSIOLOGY; PSEUDOBULBAR AFFECT; PSYCHIATRIC DIAGNOSIS; REVIEW; SEDATION; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; SPASTICITY; STROKE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ADRENERGIC ALPHA-ANTAGONISTS; BRAIN; CLINICAL TRIALS AS TOPIC; CRYING; DEXTROMETHORPHAN; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; LAUGHTER; PSEUDOBULBAR PALSY; QUINIDINE; SYNAPTIC TRANSMISSION;

EID: 79959920595     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.68     Document Type: Review

References (72)

1. Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J. Neuropsychiatry Clin. Neurosci. 17(4), 447-454 (2005 (Pubitemid 41794037)
2. Wortzel HS, Oster TJ, Anderson CA, Arciniegas DB. Pathological laughing and crying: epidemiology, pathophysiology and treatment. CNS Drugs 22(7), 531-545 (2008). (Pubitemid 351822116)
3. Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol. Scand. 80(2), 114-117 (1989). (Pubitemid 19214652)
4. Kim SW, Shin IS, Kim JM, Lim SY, Yang SJ, Yoon JS. Mirtazapine treatment for pathological laughing and crying after stroke. Clin. Neuropharmacol. 28(5), 249-251 (2005).
5. Pratt RT. An investigation of the psychiatric aspects of disseminated sclerosis. J. Neurol. Neurosurg. Psychiatry 14(4), 326-335 (1951).
6. Feinstein A, Feinstein K, Gray T, OConnor P. Prevalence of neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch. Neurol. 54(9), 1116-1121 (1997). (Pubitemid 27396479)
7. Petracca GM, Jorge RE, Ación L, Weintraub D, Robinson RG. Frequency and correlates of involuntary emotional expression disorder in Parkinsons disease. J. Neuropsychiatry Clin. Neurosci. 21(4), 406-412 (2009).
8. Siddiqui MS, Fernandez HH, Garvan CW et al. Inappropriate crying and laughing in Parkinson disease and movement disorders. World J. Biol. Psychiatry 10(3), 234-240 (2009).
9. Strowd RE, Cartwright MS, Okun MS, Haq I, Siddiqui MS. Pseudobulbar affect: prevalence and quality of life impact in movement disorders. J. Neurol. 257(8), 1382-1387 (2010).
10. Starkstein SE, Migliorelli R, Teson A et al. Prevalence and clinical correlates of pathological affective display in Alzheimers disease. J. Neurol. Neurosurg. Psychiatry 59(1), 55-60 (1995).
11. Zeilig G, Drubach DA, Katz-Zeilig M, Karatinos J. Pathological laughter and crying in patients with closed traumatic brain injury. Brain Inj. 10(8), 591-597 (1996). (Pubitemid 26289623)
12. Tateno A, Jorge RE, Robinson RG. Pathological laughing and crying following traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 16(4), 426-434 (2004). (Pubitemid 39648343)
13. Sacco S, Sar M, Pistoia F, Conson M, Albertini G, Carolei A. Management of pathologic laughter and crying in patients with locked-in syndrome: a report of 4 cases. Arch. Phys. Med. Rehabil. 89(4), 775-778 (2008). (Pubitemid 351406310)
14. Arciniegas DB, Lauterbach EC, Anderson KE et al. The differential diagnosis of pseudobulbar affect (PBA). Distinguishing PBA among disorders of mood and affect. Proceedings of a roundtable meeting. CNS Spectr. 10(5), 1-14 (2005).
15. Arciniegas DB, Topkoff J. The neuropsychiatry of pathologic affect: an approach to evaluation and treatment. Semin. Clin. Neuropsychiatry 5(4), 290-306 (2000).
16. Cummings JL, Arciniegas DB, Brooks BR et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 11(Suppl. 6), 1-7 (2006
17. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. Am. J. Psychiatry 150(2), 286-293 (1993 (Pubitemid 23046517)
18. Schiffer R, Herndon RM, Rudick RA. Treatment of pathological laughing and weeping with amitriptyline. N. Engl. J. Med. 312(23), 1480-1482 (1985). (Pubitemid 15059233)
19. Phuong L, Garg S, Duda JE, Stern MB, Weintraub D. Involuntary emotional expression disorder (IEED) in Parkinsons disease. Parkinsonism Relat. Disord. 15(7), 511-515 (2009).
20. Calvert T, Knapp P, House A. Psychological associations with emotionalism after stroke. J. Neurol. Neurosurg. Psychiatry 65(6), 928-929 (1998). (Pubitemid 128710438)
21. Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K. Fluoxetine improves emotional incontinence. Brain Inj. 6(3), 267-270 (1992).
22. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Lancet 342(8875), 837-839 (1993). (Pubitemid 23285912)
23. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatr. Scand. 98(6), 455-458 (1998). (Pubitemid 28566296)
24. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin. Neuropharmacol. 19(6), 532-551 (1996).
25. Panzer MJ, Mellow AM. Antidepressant treatment of pathologic laughing or crying in elderly stroke patients. J. Geriatr. Psychiatry Neurol. 5(4), 195-199 (1992).
26. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br. Med. Bull. 65, 193-207 (2003). (Pubitemid 36406467)
27. Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR. Pathological laughter and crying: a link to the cerebellum. Brain 124(Pt 9), 1708-1719 (2001 (Pubitemid 32845433)
28. Ghaffar O, Chamelian L, Feinstein A. Neuroanatomy of pseudobulbar affect: a quantitative MRI study in multiple sclerosis. J. Neurol. 255(3), 406-412 (2008).
29. Wilson SAK. Some problems in neurology. J. Neurol. Psychopathol. 4, 299-333 (1924).
30. Parvizi J, Coburn KL, Shillcutt SD et al. Neuroanatomy of pathological laughing and crying: a report of the American Neuropsychiatric Association Committee on Research. J. Neuropsychiatry Clin. Neurosci. 21(1), 75-87 (2009
31. Haiman G, Pratt H, Miller A. Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. J. Neurol. Sci. 271(1-2), 137-147 (2008
32. von Bohlen und Halbach O, Dermietzel R. Serotonin (5-hydroxytryptamine). In:Neurotransmitters and Neuromodulators: Handbook of Receptors and Biological Effects (Second Edition) . von Bohlen und Halbach O, Dermietzel R (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 132-143 (2006).
33. Petty F, Davis LL, Kabel D, Kramer GL. Serotonin dysfunction disorders: a behavioral neurochemistry perspective. J. Clin. Psychiatry 57(Suppl. 8), 11-16 (1996). (Pubitemid 26282186)
34. von Bohlen und Halbach O, Dermietzel R. Glutamate and aspartate. In:Neurotransmitters and Neuromodulators: Handbook of Receptors and Biological Effects (Second Edition) . von Bohlen und Halbach O, Dermietzel R (Eds). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 90-107 (2006).
35. Brooks BR, Thisted RA, Appel SH et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 63(8), 1364-1370 (2004). (Pubitemid 39426266)
36. Haiman G, Pratt H, Miller A. Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect. J. Clin. Psychopharmacol. 29(5), 444-452 (2009).
37. Andersen G, Ingeman-Nielsen M, Vestergaard K, Riis JO. Pathoanatomic correlation between poststroke pathological crying and damage to brain areas involved in serotonergic neurotransmission. Stroke 25(5), 1050-1052 (1994). (Pubitemid 24130315)
38. Famularo G, Corsi FM, Minisola G, De Simone C, Nicotra GC. Cerebellar tumour presenting with pathological laughter and gelastic syncope. Eur. J. Neurol. 14(8), 940-943 (2007). (Pubitemid 47106765)
39. Parvizi J, Schiffer R. Exaggerated crying and tremor with a cerebellar cyst. J. Neuropsychiatry Clin. Neurosci. 19(2), 187-190 (2007). (Pubitemid 46649643)
40. Tei H, Sakamoto Y. Pontine infarction due to basilar artery stenosis presenting as pathological laughter. Neuroradiology 39(3), 190-191 (1997). (Pubitemid 27135776)
41. Arif H, Mohr JP, Elkind MS. Stimulus-induced pathologic laughter due to basilar artery dissection. Neurology 64(12), 2154-2155 (2005). (Pubitemid 40881020)
42. Oh K, Kim HJ, Kim BJ, Park KW, Lee DH. Pathological laughter as an unusual manifestation of acute stroke. Eur. Neurol. 59(1-2), 83-84 (2008). (Pubitemid 350277267)
43. Lauterbach EC, Price ST, Spears TE, Jackson JG, Kirsh AD. Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in thalamic infarct associated with myoclonus and blepharospasm. Biol. Psychiatry 35(7), 488-490 (1994).
44. Ramnani N. The primate cortico-cerebellar system: anatomy and function. Nature Rev. 7(7), 511-522 (2006). (Pubitemid 43989772)
45. Stoodley CJ, Schmahmann JD. Evidence for topographic organization in the cerebellum of motor control versus cognitive and affective processing. Cortex 46(7), 831-844 (2010
46. Schmahmann JD, Weilburg JB, Sherman JC. The neuropsychiatry of the cerebellum - insights from the clinic. Cerebellum 6(3), 254-267 (2007 (Pubitemid 47360063)
47. Schmahmann JD, Sherman JC. The cerebellar cognitive affective syndrome. Brain 121(Pt 4), 561-579 (1998). (Pubitemid 28162120)
48. Parvizi J, Joseph J, Press DZ, Schmahmann JD. Pathological laughter and crying in patients with multiple system atrophy-cerebellar type. Mov. Disord. 22(6), 798-803 (2007). (Pubitemid 46800100)
49. Holtzman T, Rajapaksa T, Mostofi A, Edgley SA. Different responses of rat cerebellar Purkinje cells and Golgi cells evoked by widespread convergent sensory inputs. J. Physiol. 574(Pt 2), 491-507 (2006).
50. Barmack NH, Yakhnitsa V. Functions of interneurons in mouse cerebellum. J. Neurosci. 28(5), 1140-1152 (2008). (Pubitemid 351186350)
51. Crowley JJ, Fioravante D, Regehr WG. Dynamics of fast and slow inhibition from cerebellar Golgi cells allow flexible control of synaptic integration. Neuron 63(6), 843-853 (2009).
52. Prsa M, Dash S, Catz N, Dicke PW, Thier P. Characteristics of responses of Golgi cells and mossy fibers to eye saccades and saccadic adaptation recorded from the posterior vermis of the cerebellum. J. Neurosci. 29(1), 250-262 (2009).
53. Dean P, Porrill J, Ekerot CF, Jörntell H. The cerebellar microcircuit as an adaptive filter: experimental and computational evidence. Nat. Rev. Neurosci. 11(1), 30-43 (2010).
54. Werling LL, Keller A, Frank JG, Nuwayhid SJ. A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder. Exp. Neurol. 207(2), 248-257 (2007). (Pubitemid 47429659)
55. Kim JS. Pathologic laughter after unilateral stroke. J. Neurol. Sci. 148(1), 121-125 (1997). (Pubitemid 27149534)
56. Ferentinos P, Paparrigopoulos T, Rentzos M, Evdokimidis I. Duloxetine for pathological laughing and crying. Int. J. Neuropsychopharmacol. 12(10), 1429-1430 (2009).
57. Müller U, Murai T, Bauer-Wittmund T, von Cramon DY. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Inj. 13(10), 805-811 (1999). (Pubitemid 29488207)
58. Burns A, Russell E, Stratton-Powell H, Tyrell P, ONeill P, Baldwin R. Sertraline in stroke-associated lability of mood. Int. J. Geriatr. Psychiatry 14(8), 681-685 (1999). (Pubitemid 29403287)
59. Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 37(1), 156-161 (2006 (Pubitemid 43732065)
60. Miller A, Panitch H. Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect. J. Neurol. Sci. 259(1-2), 67-73 (2007). (Pubitemid 47039242)
61. Hackett ML, Yang M, Anderson CS, Horrocks JA, House A. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database Syst. Rev. (2), CD003690 (2010).
62. Murray V, von Arbin M, Bartfai A et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. J. Clin. Psychiatry 66(6), 708-716 (2005). (Pubitemid 40942416)
63. Panitch HS, Thisted RA, Smith RA et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann. Neurol. 59(5), 780-787 (2006). (Pubitemid 43673155)
64. Pope LE, Khalil MH, Berg JE, Stiles M, Yakatan GJ, Sellers EM. Pharmacokinetics of dextromethorphan after single or multiple dosing in combination with quinidine in extensive and poor metabolizers. J. Clin. Pharmacol. 44(10), 1132-1142 (2004). (Pubitemid 39202458)
65. Bermack JE, Debonnel G. Distinct modulatory roles of s receptor subtypes on glutamatergic responses in the dorsal hippocampus. Synapse 55(1), 37-44 (2005). (Pubitemid 39565226)
66. Craviso GL, Musacchio JM. High-affinity dextromethorphan binding sites in guinea pig brain. I. Initial characterization. Mol. Pharmacol. 23(3), 619-628 (1983). (Pubitemid 13089779)
67. Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and s-1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res. Rev. 37(1-3), 116-132 (2001). (Pubitemid 34020726)
68. Pioro EP, Brooks BR, Cummings J et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann. Neurol. 68(5), 693-702 (2010
69. Moore SR, Gresham LS, Bromberg MB, Kasarkis EJ, Smith RA. A self report measure of affective lability. J. Neurol. Neurosurg. Psychiatry 63(1), 89-93 (1997). (Pubitemid 27317366)
70. Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult. Scler. 10(6), 679-685 (2004). (Pubitemid 39585248)
71. Thisted RA, Klaff L, Schwartz SL et al. Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study. Clin. Ther. 28(10), 1607-1618 (2006). (Pubitemid 44848367)
72. Pioro EP, Brooks BR, Cummings J et al. Persistent efficacy of dextromethorphan (DM)/quinidine (Q) for pseudobulbar affect (PBA): results from a 12-Week, Open-Label Extension (OLE) Study. Presented at: 62nd American Academy of Neurology Annual Meeting. Toronto, Ontario, Canada, 10-17 April 2010